|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
 Malcolm Mitchell,
Medicial Director, Clinical Pharmacology Eli Lilly and Company Appearing: Day Two, Thursday 21 October 2010 8.50am Opening Remarks From the Chair Malcolm Mitchell, Medicial Director, Clinical Pharmacology,
Eli Lilly and Company 12pm PANEL SESSION: Strategies to Identify and Mitigate Risk in Early Clinical TrialsDirector of Toxicology,
Takeda Global R&D Malcolm Mitchell, Medicial Director, Clinical Pharmacology,
Eli Lilly and Company Dr Andrea Pellacani, Senior Director, Clinical Researc, Therapeutic Area Lea, Early Development Biologics,
Merck Ltd |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
